Multiple Myeloma Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotech, CASI Pharma, Sorrento Therap

Posted on
by

Multiple Myeloma Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotech, CASI Pharma, Sorrento Therap
The Key Multiple Myeloma Companies in the market include – Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others.

 

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Multiple Myeloma, offering comprehensive insights into the Multiple Myeloma revenue trends, prevalence, and treatment landscape. The report delves into key Multiple Myeloma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Multiple Myeloma therapies. Additionally, we cover the landscape of Multiple Myeloma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Multiple Myeloma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Multiple Myeloma space.

 

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

 

Some of the key facts of the Multiple Myeloma Market Report:

  • The Multiple Myeloma market size was valued ~USD 21,300 in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In 2023, the total multiple myeloma market in the US was approximately USD 14,300 million, with projections indicating growth by 2034.

  • In the 4L+ treatment setting, approved CAR-T therapies (ABECMA and CARVYKTI) were projected to generate approximately USD 828 million in the US in 2023, with further growth anticipated as additional CAR-T therapies receive approval during the forecast period.

  • In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5–25 mg), a treatment for multiple myeloma and certain cases of myelodysplastic syndromes (MDS). The product, bioequivalent to Bristol-Myers Squibb’s Revlimid®, will be manufactured at Lupin’s Pithampur facility in India.

  • In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.

  • In May 2025, GSK announced that the CHMP of the EMA recommended approval of Blenrep for adults with relapsed or refractory multiple myeloma. The recommendation covers use with bortezomib and dexamethasone (BVd) for patients with at least one prior therapy, and with pomalidomide and dexamethasone (BPd) for those previously treated with lenalidomide. A final decision from the European Commission is expected in Q3 2025.

  • In May 2025, Johnson & Johnson announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM). The FDA application for this indication was submitted in November 2024.

  • In April 2025, Halozyme announced that the European Commission approved an indication extension for subcutaneous DARZALEX® (daratumumab) co-formulated with ENHANZE®. The new approval allows its use with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) in newly diagnosed multiple myeloma patients.

  • In March 2025, the FDA issued its first untitled letter to Edenbridge Pharmaceuticals (now Dexcel Pharma) over a promotional panel for Hemady. Triggered by a Bad Ad complaint, the FDA flagged omitted information and weak study data. Hemady, an oral dexamethasone formulation, provides 20 mg per tablet to reduce pill burden in multiple myeloma patients.

  • In February 2025, Opna Bio announced that its oral small molecule inhibitor, OPN-6602, received FDA Orphan Drug designation for multiple myeloma. OPN-6602 targets E1A-binding protein (EP300) and CREB-binding protein (CBP).

  • Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others

  • Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA

  • The Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Myeloma pipeline products will significantly revolutionize the Multiple Myeloma market dynamics.

  • In 2023, the total incidence of multiple myeloma across the 7MM was approximately 75,000 cases, with numbers expected to rise over the forecast period.

  • Within the 7MM, the United States reported the highest incidence of multiple myeloma, followed by the EU4 countries and the UK.

  • In 2023, within the EU4 and the UK, Germany recorded the highest number of new multiple myeloma cases, while Spain reported the lowest.

  • Multiple myeloma occurs more frequently in males than females, with over 50% of cases in the United States diagnosed in men.

  • Data indicates that approximately half of newly diagnosed multiple myeloma patients are not eligible for transplant, and about one-third of those who are eligible do not undergo the procedure. In 2023, the US had roughly 23,600 frontline transplant-ineligible and 9,200 transplant-eligible multiple myeloma patients.

  • In terms of age-specific incidence, individuals aged 65 and above represent the largest proportion of multiple myeloma cases in the United States, accounting for over 70% of cases, followed by those aged 55–64 and 0–54 years.

 

Multiple Myeloma Overview

Multiple Myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. In MM, abnormal plasma cells multiply uncontrollably in the bone marrow, leading to impaired immune function, bone damage, anemia, kidney problems, and increased risk of infections. The disease is typically chronic and progresses over time, with symptoms including bone pain, fatigue, frequent infections, and high calcium levels. Treatment often involves a combination of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care to manage symptoms and slow disease progression.

 

Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/multiple-myeloma-market

 

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Multiple Myeloma

  • Prevalent Cases of Multiple Myeloma by severity

  • Gender-specific Prevalence of Multiple Myeloma

  • Diagnosed Cases of Episodic and Chronic Multiple Myeloma

 

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast

 

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Myeloma Therapies and Key Companies

  • Zevorcabtagene Autoleucel: Carsgen Therapeutics

  • Descartes 08: Cartesian Therapeutics

  • GC012F: Gracell Biotechnology Shanghai Co., Ltd.

  • CID-103: CASI Pharmaceuticals

  • STI-1492: Sorrento Therapeutics

  • CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine

  • TALVEY (talquetamab): Johnson & Johnson Innovative Medicine

  • ABECMA: Bristol-Myers Squibb and Bluebird bio

  • SARCLISA: Sanofi

 

Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape

 

Multiple Myeloma Market Drivers

  • Rising global prevalence of multiple myeloma due to aging populations.

  • Advances in targeted therapies, immunotherapies, and CAR-T cell treatments improving patient outcomes.

  • Increasing adoption of novel combination therapies and personalized medicine approaches.

  • Growing awareness and early diagnosis through improved diagnostic technologies.

  • Expansion of reimbursement and healthcare infrastructure in emerging markets.

 

Multiple Myeloma Market Barriers

  • High cost of innovative therapies limiting patient access, especially in developing regions.

  • Complex treatment regimens leading to patient non-compliance.

  • Safety and adverse effect concerns associated with long-term therapy.

  • Limited availability of specialized treatment centers for advanced therapies like CAR-T.

  • Regulatory hurdles and lengthy approval timelines for new drugs.

 

Scope of the Multiple Myeloma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others

  • Key Multiple Myeloma Therapies: Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others

  • Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies

  • Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement

 

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Multiple Myeloma Market Report Introduction

2. Executive Summary for Multiple Myeloma

3. SWOT analysis of Multiple Myeloma

4. Multiple Myeloma Patient Share (%) Overview at a Glance

5. Multiple Myeloma Market Overview at a Glance

6. Multiple Myeloma Disease Background and Overview

7. Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Myeloma

9. Multiple Myeloma Current Treatment and Medical Practices

10. Multiple Myeloma Unmet Needs

11. Multiple Myeloma Emerging Therapies

12. Multiple Myeloma Market Outlook

13. Country-Wise Multiple Myeloma Market Analysis (2020–2034)

14. Multiple Myeloma Market Access and Reimbursement of Therapies

15. Multiple Myeloma Market Drivers

16. Multiple Myeloma Market Barriers

17. Multiple Myeloma Appendix

18. Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/